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Objectives: Production of carbapenemase, especially Klebsiella pneumoniae
carbapenemases (KPC), is one of the antibiotic resistance mechanisms of
Enterobacteriaceae such as Klebsiella oxytoca. This study aimed to investigate
and identify KPC-producing K. oxytoca isolates using molecular and phenotypic
methods.
Methods: A total of 75 isolates of K. oxytoca were isolated from various clinical
samples, and were verified as K. oxytoca after performing standard microbio-
logical tests and using a polymerase chain reaction (PCR) method. An antibiotic
susceptibility test was performed using a disc diffusion method according to the
Clinical and Laboratory Standards Institute guidelines. CHROMagar KPC chro-
mogenic culture media was used to examine and confirm the production of the
carbapenemase enzyme in K. oxytoca isolates; in addition, PCR was used to
evaluate the presence of blaKPC gene in K. oxytoca strains.
Results: Of a total of 75 K. oxytoca isolates, one multidrug resistant strain was
isolated from the urine of a hospitalized woman. This strain was examined to
assess its ability to produce carbapenemase enzyme; it produced a colony with a
blue metallic color on the CHROMagar KPC chromogenic culture media. In
addition, the blaKPC gene was confirmed by PCR. After sequencing, it was
confirmed and deposited in GenBank.
Conclusion: To date, many cases of KPC-producing Enterobacteriaceae, in
particular K. pneumoniae, have been reported in different countries; there are
also some reports on the identification of KPC-producing K. oxytoca. Therefore,Soltan Dallal).
ase Control and Prevention. Published by Elsevier Korea LLC. This is an open access article
reativecommons.org/licenses/by-nc-nd/4.0/).
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and prevention of the spread of these strains are of great importance.1. Introduction
According to Ambler classification, b-lactamases are
categorized into four classes (AeD) based on their
molecular structure (sequence of amino acids and
nucleic acids). Class A includes the genes for TEM,
SHV, CTX-M, and Klebsiella pneumoniae carbapene-
mases (KPC) b-lactamase enzymes. KPC can hydrolyze
a range of b-lactams including third-generation cepha-
losporins, monobactams, and carbapenems. Klebsiella
pneumoniae carbapenemase (KPC), which is classified
as a molecular class A b-lactamase, is a serious clinical
challenge. In addition, KPC-producing Enterobacteri-
aceae isolates, especially KPC-producing K. pneumo-
niae isolates, are rapidly spreading all over the world.
The worldwide emergence and spread of carbapenem-
resistant Enterobacteriaceae isolates is a challenge for
physicians and clinical microbiologists [1]. Therefore,
early diagnosis and prevention of strain dissemination is
a medical emergency [2].
KPCs are not just limited to the K. pneumoniae
strain, and nowadays KPCs are also found extensively in
other bacteria such as Escherichia coli, Enterobacter
spp., Serratia spp., Morganella morganii, Citrobacter
freundii, Salmonella enterica, Klebsiella oxytoca, Aci-
netobacter spp., Pseudomonas aeruginosa, and Pseu-
domonas putida [3,4]. To date, a total of 24 genotypes
have been identified [5], and KPC-2 and KPC-3 are the
most common genotypes isolated from clinical speci-
mens. Among the identified genotypes, KPC-2 is the
most dominant genotype worldwide [6,7]. The KPC
gene is on transposon Tn 4401, which facilitates the
transmission between plasmids and bacterial species
from a bacterium to other bacteria, from one patient to
another, and even from one country to another; it can
also generate multidrug-resistant strains [8]. KPC-
producing K. pneumoniae isolates have high levels of
antibiotic resistance; because of the plasmid transfer of
the KPC gene to other genes and species of Entero-
bacteriaceae, they have been responsible for many out-
breaks of nosocomial infections in the world in recent
years. In addition, there have been many reports on the
identification of KPC-producing strains of Enterobac-
teriaceae, in particular K. pneumoniae, in different
countries [9].
The first case of KPC-producing K. pneumoniae was
identified and introduced in North Carolina in 2001
through Project Intensive Care Antimicrobial Resistance
Epidemiology [10]. From 1990 to 2015, there were many
studies that reported the identification of the first cases of
KPC-producing K. pneumoniae isolates in differentcountries such as USA, Canada, Italy, Poland, France,
Spain, UK, Colombia, India, Argentina, China, Ireland,
Greece, Brazil, Turkey, Japan, South Korea, and Iran
[9e17]. KPC-producing K. oxytoca isolates are rarely
reported [18]. K. oxytoca is an opportunistic pathogen
and is now identified and introduced as an important
clinical pathogen that is associated with nosocomial in-
fections in hospitalized patients, including children,
newborns, and individuals with immune deficiency [19].
A few studies have reported the identification of the KPC
gene in K. oxytoca strains in some countries such as
Austria [18], Brazil [20], and Venezuela [21]. Identifi-
cation of this gene plays an important role in the study of
K. oxytoca antibiotic resistance. This study aimed to
evaluate the use of phenotypic method (CHROMagar
KPC chromogenic culture media) and a polymerase
chain reaction (PCR) method for the identification of
KPC-producing K. oxytoca isolates. In this study, we
report the first detection of the blaKPC gene among iso-
lates of K. oxytoca in Iran.2. Materials and methods
2.1. Bacterial isolates
A total of 75 K. oxytoca strains were collected from
several hospitals in Tehran between 2013 and 2014.
Clinical strains were isolated from stool, blood, urine,
sputum, and wounds.
2.2. Microbiological methods
Using standard microbiological tests in the labora-
tory, all bacterial isolates were identified as K. oxytoca.
In addition, all K. oxytoca isolates were also identified
and confirmed by PCR method, which was performed
through the amplification of galacturonase specific gene
(pehX ).
PCR was performed through the amplification of 344
base pairs (bp) specific to K. oxytoca. To amplify pehX
gene we used the forward primer PEH C (50-GAT ACG
GAG TAT GCC TTT ACG GTG-30) and reverse primer
PEH D (50-TAG CCT TTA TCA AGC GGA TAC TTG-
30) [22].
2.3. Antimicrobial susceptibility testing
Susceptibility testingof isolateswas performed bydisc-
diffusion method, using antibiotic discs manufactured by
MASTCompany (Bootle,Merseyside,UK) and according
to criteria recommended by the Clinical and Laboratory
Standards Institute [23]. Antibiotic discs used were:
getamycin (10 mg), imipenem (10 mg), meropenem
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cillin (10 mg), amoxicillin (25 mg), aztreonam (30 mg),
ceftriaxone (30mg), cefepime (30mg), cefuroxime (30mg),
ticarcillin (75 mg), ceftazidime (30 mg), amikacin (30 mg),
ampicillin/sulbactam (20 mg), cephalothin (30 mg), and
trimethoprim/sulfamethoxazole (25 mg).
2.4. Molecular detection of blaKPC gene
Genomic DNA of K. oxytoca isolates was obtained
through boiling two or three colonies in 500 mL of
distilled water for 10 minutes and centrifugation for
10 minutes at 10,000 rpm. The supernatants were then
used as a template for amplification [24]. To identify
the blaKPC gene, KPC-Forward and KPC-Reverse
primers, with the following sequences, were used:
KPC-Forward: 50-CAG CTC ATT CAA GGG CTT
TC-30, KPC-Reverse: 50-AGT CAT TTG CCG TGC
CAT AC-30 [25]. PCR reaction was performed in a
final volume of 20 mL. To perform each PCR reaction,
we used 10 mL Master mix (Ampliqon, Odense,
Denmark), 0.5 mL forward primer 10 pmol (Bioneer,
Daejeon, Korea), 0.5 mL reverse primer 10 pmol
(Bioneer), 8.5 mL distilled water, and 50 ng of bacterial
DNA.
PCR reaction was performed in a thermocycler
(PEQLAB, Erlangen, Germany) with an initial dena-
turation at 95C for 5 minutes; and 35 cycles including
denaturation steps at 94C for 45 seconds, the annealing
at 52C for 45 seconds, the extension at 72C for
45 seconds, and final extension at 72C for 10 minutes.
The electrophoresis of the PCR products was performed
in a 1% agarose gel. The gel was stained using ethidium
bromide (50 mg/L) and DNA detected by Gel Doc
(GVM20 model; Syngene, Cambridge, UK). The posi-
tive PCR product for sequencing was submitted to
Macrogen, Inc. (Seoul, Korea). A KPC-producing K.
pneumoniae strain with accession number JX966417
was used as a positive control strain.
2.5. Detection by use of chromogenic medium
To study the production of carbapenemase enzyme in
isolates of K. oxytoca, we used the CHROMagar chro-
mogenic media (CHROMagar, Paris, France) [6,7,26].
The K. oxytoca strains were isolated from clinical
specimens cultured in the prepared CHROMagar me-
dium. K. oxytoca strains that produce carbapenemase
enzyme are detected when they produce a colony with a
blue metallic color on this chromogenic culture media.3. Results
A total of 75 K. oxytoca isolates from clinical spec-
imens were collected from stool (9.3%), blood (14.7%),
urine (68%), sputum (5.3%), and wounds (2.7%) of
patients in four hospitals in Tehran between 2013 and2014. The primary assessment of isolated strains showed
that all strains had a galacturonase-specific gene and
they were identified as K. oxytoca isolates. Antibiotic
susceptibility test was performed for all the examined
isolates (Table 1) and we identified a multidrug-resistant
phenotype.
The PCR confirmed the presence of blakpc gene; in
addition, the presence of carbapenemase enzyme was
confirmed by the production of a colony with a blue
metallic color on CHROMagar culture media
(Figure 1). Hence the isolate was identified as a strain
of KPC-producing K. oxytoca. This strain was isolated
from a urine sample of a 73-year-old female patient
admitted to a women’s surgery ward. First, using
standard microbiological tests and using PCR, it was
identified as a K. oxytoca strain. Antibiotic suscepti-
bility test which was performed using a disc-diffusion
method showed that this isolate was resistant to imi-
penem, cefepime, cefotaxime, ceftazidime, amikacin,
kanamycin, ciprofloxacin, aztreonam, cefazolin, and
sulfamethoxazole/trimethoprim. A molecular method
then confirmed the presence of the blaKPC gene in this
isolate (Figure 2).
Sequence analysis of the blakpc gene revealed that it
was 99% identical to the other of the blaKPC genes
deposited in GenBank database. The nucleotide
sequence of the blaKPC gene, which was determined in
our study, was assigned to the GenBank nucleotide
sequence database under the accession number
KU057943.
4. Discussion
Many studies have reported the identification of
Gram-negative bacteria producing class A, B, C, D
carbapenemases in the Middle East [27]. In recent years,
many cases of KPC-producing Enterobacteriaceae, in
particular K. pneumoniae, have been reported in
different countries [7,9,26,28]. KPC-producing K. oxy-
toca isolates are rarely reported in various parts of the
world [28]. In this study, first the K. oxytoca isolates
were examined in terms of the presence of KPC gene by
using molecular and phenotypic methods. In study by
Samra et al [26], chromogenic medium CHROMagar
KPC was shown to have a sensitivity of 100% and
specificity of 98.4% relative to PCR. The CHROMagar
chromogenic KPC culture media was used as a KPC
screening method. One isolate was identified as a posi-
tive KPC. After sequencing, it was confirmed and
deposited in GenBank. This is the first case of KPC-
producing K. oxytoca ever detected and reported in
Iran, although others studies have detected KPC-
producing P. aeruginosa and Acinetobacter baumannii
isolates [29,30]. In July 2012, Nobari et al [17] identi-
fied a strain of K. pneumoniae blaKPC gene that was
isolated from the urine of a female patient hospitalized
Table 1. Antimicrobial susceptibility patterns of all Klebsiella oxytoca isolated in this study.
Antibiotic Susceptible, n (%) Intermediate, n (%) Resistant, n (%)
GM 67 (89.3) 1 (1.3) 7 (9.4)
AK 66 (88) 7 (9.3) 2 (2.7)
IMI 74 (98.7) 0 (0) 1 (1.3)
MEM 74 (98.7) 0 (0) 1 (1.3)
AP 14 (18.7) 2 (2.7) 59 (78.6)
A 14 (18.7) 3 (4) 58 (77.3)
SAM 58 (77.3) 3 (4) 14 (18.7)
TC 9 (12) 5 (6.7) 61 (81.3)
ATM 72 (96) 0 (0) 3 (4)
CRO 56 (74.7) 5 (6.7) 14 (18.6)
CTX 53 (70.) 7 (9.3) 15 (20)
CPM 64 (85.3) 2 (2.7) 9 (12)
KF 55 (73.3) 3 (4) 17 (22.7)
CAZ 61 (81.3) 6 (8) 8 (10.7)
CXM 66 (88) 0 (0) 9 (12)
TS 48 (64) 2 (2.7) 25 (33.3)
CIP 56 (74.7) 6 (8) 13 (17.3)
A Z amoxicillin; AK Z amikacin; AP Z ampicillin; ATM Z aztreonam; CAZ Z ceftazidime; CIP Z ciprofloxacin; CPM Z cefepime;
CRO Z ceftriaxone; CTX Z cefotaxime; CXM Z cefuroxime; GM Z gentamycin; IMI Z imipenem; KF Z cephalothin; MEM Z meropenem;
SAM Z ampicillin/sulbactam; TC Z ticarcillin; TS Z trimethoprim/sulfamethoxazole.
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first case of K. pneumoniae blaKPC gene in Iran. Some
cases of K. oxytoca have also been identified and re-
ported in Brazil [20] and Venezuela [21]. A study in
Austria reported the identification of 31 strains of KPC-
producing K. oxytoca isolated from five patients hospi-
talized in Intensive Care Unit wards [1]. In the present
study, one carbapenem-resistant isolate of K. oxytoca
was recovered. Antibiotic susceptibility test results
showed that highest and lowest resistances were related
to ticarcillin (81.3%) and meropenem and imipenem
(1.3%), respectively.Figure 1. Electrophoresis of PCR products amplified from
KPC gene in 1% agarose gel. Lane 1, positive control; Lane 2,
negative isolate; Lane 3, positive isolate; Lane 4, negative
control; M, 100 bp ladder.Because of high antibiotic resistance, the location of
the KPC gene on Tn 4401 transposons, and plasmid
transfer of the genes to other species of Enterobacteri-
aceae, KPC-producing K. pneumoniae and K. oxytoca
isolates are often associated with nosocomial infections
[8]. These isolates can rapidly disseminate and lead to
widespread resistance; in recent years, they have been
responsible for outbreaks of nosocomial infections
around the world [3,7,9]. Since the identification and
prevalence of KPC-producing Enterobacteriaceae is
considered a medical emergency, timely diagnosis,
control, and prevention the spread of bacteria is of great
importance. The mortality rate associated with KPC-
producing bacterial infections is 22e59% [7]; thus,
after the emergence of KPC-producing bacteria, the
main challenge is to treat infections caused by these
bacteria. However, the treatment is very difficult and
therefore the mortality rate is high [8]. Given the
increasing prevalence of carbapenem-resistant Entero-
bacteriaceae isolates, KPC-producing bacteria are
spreading in the community and in the hospitals;
therefore, it is going to become a treatment challenge
that requires some necessary measures to control the
disease and successfully treat the infections.
To date, many cases of KPC-producing Enterobac-
teriaceae, in particular K. pneumoniae, have been re-
ported in different countries; there are also some reports
about the identification of KPC-producing K. oxytoca in
some countries. In this study, we reported the first
detection of the blaKPC gene among isolates of K. oxy-
toca in Iran. This study showed that there is an urgent
need for the implementation of strategies to control the
dissemination of KPC-producing K. oxytoca isolates.
Figure 2. The growth of K. oxytoca in CHROMagar KPC
medium and produce carbapenamase by produce metallic blue
colonies.
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